News & Updates
Showing Endocrinology articles
Showing

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

What do young T1DM patients look for in ketone breath sensors?
Young patients with type 1 diabetes mellitus (T1DM) find the noninvasive nature of ketone breath sensor devices attractive, especially as compared with blood testing, according to a recent study. Still, concerns about such devices remain, including their ease of use, accuracy, and affordability.

Overweight, obesity do not worsen disease activity for children with IBD
In children with newly diagnosed inflammatory bowel disease (IBD), overweight and obese status are not associated with worse disease activity at 1 year after diagnosis compared with normal weight, results of a study have shown.

SGLT2 inhibitors show renal benefits vs GLP-1 RAs in T2D patients in the real world
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.




